Low CYP24A1 mRNA expression and its role in prognosis of breast cancer

被引:0
|
作者
Hongqiao Cai
Yan Jiao
Yanqing Li
Zhaoying Yang
Miao He
Yahui Liu
机构
[1] The First Hospital of Jilin University,Department of Hepatobiliary and Pancreatic Surgery
[2] Jilin University,Department of Pathophysiology, College of Basic Medical Sciences
[3] China-Japan Union Hospital of Jilin University,Department of Breast Surgery
[4] The Second Hospital of Jilin University,Department of Anesthesia
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Breast cancer is the most common malignant cancer in women. CYP24A1 expression regulates cellular response to vitamin D, which has antitumor effects against breast cancer. This study aimed to identify the correlation between CYP24A1 mRNA expression and prognosis of breast cancer. This study enrolled 1102 patients, including 1090 females and 12 males, from TCGA-BRCA cohort. The Cancer Genome Atlas database was used to study CYP24A1 mRNA expression in breast cancer, and Chi-squared tests were performed to test the correlation between clinical features and CYP24A1 expression. The prognostic value of CYP24A1 in breast cancer was assessed using Kaplan–Meier curves and Cox analysis. Low CYP24A1 expression was associated with age, molecular subtype, ER, PR, HER2, menopause status, N classification, vital status, overall survial and relapse-free survival. CYP24A1 presented a moderate diagnostic ability in breast cancer. Furthermore, low CYP24A1 expression was correlated with poor prognosis. CYP24A1 was an independent risk factor for breast cancer. CYP24A1 plays an important role in prognosis of breast cancer. CYP24A1 has the potential to be a biomarker, especially in predicting prognosis.
引用
收藏
相关论文
共 50 条
  • [1] Low CYP24A1 mRNA expression and its role in prognosis of breast cancer
    Cai, Hongqiao
    Jiao, Yan
    Li, Yanqing
    Yang, Zhaoying
    He, Miao
    Liu, Yahui
    [J]. SCIENTIFIC REPORTS, 2019, 9 (1)
  • [2] Expression of VDR and CYP24A1 mRNA in human tumors
    Mark G. Anderson
    Masaki Nakane
    Xiaoan Ruan
    Paul E. Kroeger
    J. Ruth Wu-Wong
    [J]. Cancer Chemotherapy and Pharmacology, 2006, 57 : 234 - 240
  • [3] Expression of VDR and CYP24A1 mRNA in human tumors
    Anderson, MG
    Nakane, M
    Ruan, XA
    Kroeger, PE
    Wu-Wong, JR
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (02) : 234 - 240
  • [4] CYP24A1 polymorphisms and breast cancer risk
    Beuy Joob
    Viroj Wiwanitkit
    [J]. Breast Cancer Research and Treatment, 2020, 180 : 525 - 525
  • [5] CYP24A1 polymorphisms and breast cancer risk
    Joob, Beuy
    Wiwanitkit, Viroj
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (02) : 525 - 525
  • [6] Implication of CYP24A1 Splicing in Breast Cancer
    Scheible, Chimi
    Thill, Marc
    Baum, Sascha
    Solomayer, Erich
    Friedrich, Michael
    [J]. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2014, 14 (01) : 109 - 114
  • [7] Role and regulation of CYP24A1 in endometrial cancer
    Bokhari, Amber A.
    Lee, Laura R.
    Dewayne, Raboteau
    Hamilton, Chad A.
    Maxwell, George L.
    Rodriguez, Gustavo C.
    Syed, Vigar
    [J]. CANCER RESEARCH, 2015, 75
  • [8] CYP24A1 is a potential biomarker for the progression and prognosis of human colorectal cancer
    Sun, Hongyan
    Wang, Chuanwen
    Hao, Miao
    Sun, Ran
    Wang, Yuqian
    Liu, Tie
    Cong, Xianling
    Liu, Ya
    [J]. HUMAN PATHOLOGY, 2016, 50 : 101 - 108
  • [9] Role of Polymorphisms of FAM13A, PHLDB1, and CYP24A1 in Breast Cancer Risk
    Wei, Ying
    Wang, Xiaolin
    Zhang, Zhe
    Xie, Mingrui
    Li, Yuyao
    Cao, Hongxin
    Zhao, Xinhan
    [J]. CURRENT MOLECULAR MEDICINE, 2019, 19 (08) : 579 - 588
  • [10] Targeting CYP24A1
    Susan J. Allison
    [J]. Nature Reviews Nephrology, 2016, 12 (4) : 196 - 196